FDA Approves First PARP Inhibitor for Prostate Cancer

Men fighting the most aggressive form of prostate cancer now have a powerful new weapon in their corner.

The FDA just approved two companion diagnostic tests that identify patients who can benefit from a groundbreaking combination therapy for metastatic castration-resistant prostate cancer. This advanced form of the disease affects men whose cancer has spread beyond the prostate and no longer responds to standard hormone treatments.

The approval pairs FoundationOne CDx and FoundationOne Liquid CDx tests with Talzenna, the first PARP inhibitor approved for use alongside the existing standard treatment Xtandi. Together, they offer personalized treatment options for patients with specific gene mutations that make their cancer particularly challenging to treat.

Here's why this matters: prostate cancer is the second most common cancer in men, with roughly one in eight diagnosed during their lifetime. When the disease progresses to its most aggressive form, doctors need every tool available to fight it effectively.

The new tests identify homologous recombination repair gene mutations, which appear in 20% to 30% of patients with advanced prostate cancer. That means potentially thousands of men each year could benefit from this tailored approach instead of a one-size-fits-all treatment.

"Every patient deserves clear, personalized answers when it comes to their treatment plan," says Dr. Todd Druley, chief medical officer at Foundation Medicine. The tissue and blood-based tests give doctors precise information about which patients will respond best to the combination therapy.

The Ripple Effect

This approval represents more than just new tests. It signals a shift toward truly personalized cancer care, where treatments match each patient's unique genetic profile.

Foundation Medicine now has nine FDA-approved companion diagnostic tests specifically for prostate cancer and more than 100 approved tests across all cancer types. Each approval opens doors for more patients to access treatments designed for their specific diagnosis.

The bigger challenge remains access. "Too many prostate cancer patients still can't access the biomarker tests that should guide their treatment," says Courtney Bugler, CEO of ZERO Prostate Cancer. The organization advocates for consistent, equitable testing regardless of a patient's location or healthcare provider.

With these new diagnostic tools now FDA-approved, more men and their families can get the clarity they need to make informed decisions about care. The tests provide concrete answers about which treatment path offers the best hope for fighting their specific type of cancer.

For patients facing an advanced prostate cancer diagnosis, personalized medicine is no longer a future promise but a present reality.